Background: Clefts of the oral-facial region usually occur in early fetal development and can affect the lip, the soft palate and the hard palate. Cleft lip (with or without cleft palate) is a genetically complex birth defect that occurs in approximately one in every 750-1,000 live births. This is one of the most common birth defects and is multifactorial, with both genetic and environmental causes. Cleft lip- and palate-associated transmembrane protein 1 (CLPTM1) belongs to a family of cleft lip and palate transmembrane proteins. This family also contains cisplatin resistance-related protein (CRR9), which is involved in CDDP-induced apoptosis. CLPTM1L (cleft lip and palate transmembrane protein 1-like protein), also known as CRR9p (cisplatin resistance-related protein 9) is a 538 amino acid multi-pass membrane protein that belongs to the CLPTM1 family and, when overexpressed, enhances cisplatin-mediated apoptosis. CLPTM1L exists as two alternatively spliced isoforms encoded by a gene that maps to human chromosome 5p15.33.
Description: Rabbit polyclonal to CLPTM1L
Immunogen: KLH conjugated synthetic peptide derived from CLPTM1L
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 62 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
